There are currently no FDA-approved medications for cocaine addiction. In the previous funding period, several animal models of cocaine abuse were used by this Center to investigate the neuropharmacology of chronic cocaine exposure. The studies described in Project 1 combine three research areas that were separated into distinct Projects in the previous version of the Center (formerly Projects 3, 5 and 6). These studies are designed to systematically investigate in monkeys and rats current medications used clinically to beat cocaine addiction, as well as drugs in the clinical """"""""pipeline"""""""" and drugs that are not approved for human use, but could provide information related to mechanisms of action related to clinical efficacy.
Specific Aim 1 will use rhesus monkeys self-administering cocaine to examine the effects of chronic administration of drugs. Treatment drugs that selective decrease cocaine- relative to food-reinforced responding, with no evidence of tolerance or attenuation by higher cocaine doses, will be evaluated in monkey models of cognition (Specific Aim 2). A positive outcome in models of cognition (i.e., improvement in performance) will yield additional studies in experimentally naive monkeys in combination with imaging studies (Projects 2 and 3). Finally, Specific Aim 3 will examine the effects of acute and chronic administration of drug treatments in several rat models of cocaine self-administration. When complete, the studies in this Project will provide basic science information in monkeys and rats across several behavioral endpoints in which different aspects of addiction are modeled, which should be of relevance to clinicians.
By combining a top-down approach, using drugs currently being evaluated clinically, with a mechanistic approach in several animal models of self-administration and cognition, areas of convergence will be identified that are relevant to identifying neuropharmacological mechanisms for effective treatment agents for cocaine addiction.
|Melchior, James R; Jones, Sara R (2017) Chronic ethanol exposure increases inhibition of optically targeted phasic dopamine release in the nucleus accumbens core and medial shell ex vivo. Mol Cell Neurosci 85:93-104|
|Blume, Lawrence C; Patten, Theresa; Eldeeb, Khalil et al. (2017) Cannabinoid Receptor Interacting Protein 1a Competition with ?-Arrestin for CB1 Receptor Binding Sites. Mol Pharmacol 91:75-86|
|John, William S; Martin, Thomas J; Nader, Michael A (2017) Behavioral Determinants of Cannabinoid Self-Administration in Old World Monkeys. Neuropsychopharmacology 42:1522-1530|
|Brodnik, Zachary D; Ferris, Mark J; Jones, Sara R et al. (2017) Reinforcing Doses of Intravenous Cocaine Produce Only Modest Dopamine Uptake Inhibition. ACS Chem Neurosci 8:281-289|
|Howlett, Allyn C; Abood, Mary E (2017) CB1 and CB2 Receptor Pharmacology. Adv Pharmacol 80:169-206|
|Gould, Robert W; Czoty, Paul W; Porrino, Linda J et al. (2017) Social Status in Monkeys: Effects of Social Confrontation on Brain Function and Cocaine Self-Administration. Neuropsychopharmacology 42:1093-1102|
|Namjoshi, Sanjeev V; Raab-Graham, Kimberly F (2017) Screening the Molecular Framework Underlying Local Dendritic mRNA Translation. Front Mol Neurosci 10:45|
|Wesley, Michael J; Lile, Joshua A; Fillmore, Mark T et al. (2017) Neurophysiological capacity in a working memory task differentiates dependent from nondependent heavy drinkers and controls. Drug Alcohol Depend 175:24-35|
|Siciliano, Cody A; Saha, Kaustuv; Calipari, Erin S et al. (2017) Amphetamine reverses escalated cocaine intake via restoration of dopamine transporter conformation. J Neurosci :|
|Luessen, D J; Sun, H; McGinnis, M M et al. (2017) Chronic intermittent ethanol exposure selectively alters the expression of G? subunit isoforms and RGS subtypes in rat prefrontal cortex. Brain Res 1672:106-112|
Showing the most recent 10 out of 301 publications